EA201491641A1 - Конденсированное бициклическое 2,4-диаминопиримидиновое производное в качестве двойного alk и fak ингибитора - Google Patents

Конденсированное бициклическое 2,4-диаминопиримидиновое производное в качестве двойного alk и fak ингибитора

Info

Publication number
EA201491641A1
EA201491641A1 EA201491641A EA201491641A EA201491641A1 EA 201491641 A1 EA201491641 A1 EA 201491641A1 EA 201491641 A EA201491641 A EA 201491641A EA 201491641 A EA201491641 A EA 201491641A EA 201491641 A1 EA201491641 A1 EA 201491641A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alk
double
condensed bicyclic
fak inhibitor
diaminopyrimidine derivative
Prior art date
Application number
EA201491641A
Other languages
English (en)
Other versions
EA025859B1 (ru
Inventor
Лоран Курвуазье (умер)
Мартин Дж. Джейкобс
Грегори Р. Отт
Шон П. Оллвейн
Original Assignee
Сефалон, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201491641(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сефалон, Инк. filed Critical Сефалон, Инк.
Publication of EA201491641A1 publication Critical patent/EA201491641A1/ru
Publication of EA025859B1 publication Critical patent/EA025859B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Настоящее изобретение относится к соединению формулы (I) или его солевой форме. Соединение формулы (I) обладает активностью, ингибирующей ALK и FAK, и их можно применять для лечения пролиферативных нарушений.
EA201491641A 2012-03-06 2013-03-06 Конденсированное бициклическое 2,4-диаминопиримидиновое производное в качестве двойного alk и fak ингибитора EA025859B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Publications (2)

Publication Number Publication Date
EA201491641A1 true EA201491641A1 (ru) 2015-04-30
EA025859B1 EA025859B1 (ru) 2017-02-28

Family

ID=47892060

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201691574A EA033124B1 (ru) 2012-03-06 2013-03-06 Применение конденсированного бициклического 2,4-диаминопиримидинового производного для лечения alk- или fak-опосредованного заболевания или нарушения у субъекта
EA201491641A EA025859B1 (ru) 2012-03-06 2013-03-06 Конденсированное бициклическое 2,4-диаминопиримидиновое производное в качестве двойного alk и fak ингибитора

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201691574A EA033124B1 (ru) 2012-03-06 2013-03-06 Применение конденсированного бициклического 2,4-диаминопиримидинового производного для лечения alk- или fak-опосредованного заболевания или нарушения у субъекта

Country Status (29)

Country Link
US (5) US9132128B2 (ru)
EP (2) EP3056494B1 (ru)
JP (2) JP6016953B2 (ru)
KR (1) KR102068374B1 (ru)
CN (2) CN104159894B (ru)
AU (1) AU2013229995B2 (ru)
CA (1) CA2865420C (ru)
CL (1) CL2014002353A1 (ru)
CY (1) CY1117565T1 (ru)
DK (1) DK2822939T3 (ru)
EA (2) EA033124B1 (ru)
ES (2) ES2681487T3 (ru)
HK (2) HK1205119A1 (ru)
HR (1) HRP20160387T1 (ru)
HU (1) HUE027976T2 (ru)
IL (2) IL234239A (ru)
ME (1) ME02460B (ru)
MX (1) MX347772B (ru)
MY (1) MY177290A (ru)
NZ (1) NZ630251A (ru)
PH (1) PH12014501979A1 (ru)
PL (1) PL2822939T3 (ru)
RS (1) RS54689B1 (ru)
SG (2) SG10201507865QA (ru)
SI (1) SI2822939T1 (ru)
SM (1) SMT201600134B (ru)
UA (1) UA115052C2 (ru)
WO (1) WO2013134353A1 (ru)
ZA (1) ZA201406147B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865420C (en) 2012-03-06 2020-06-02 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
EP3237408B1 (en) 2014-12-23 2018-10-31 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
KR20210041571A (ko) 2018-08-07 2021-04-15 인3바이오 리미티드 역형성 림프종 키나아제 억제제와 조합하여 egf/egfr 경로를 억제하기 위한 방법 및 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4836788B2 (ja) 2003-07-23 2011-12-14 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼ変調因子及びその使用法
JP4607879B2 (ja) 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
BRPI0507668A (pt) * 2004-02-14 2007-07-17 Irm Llc compostos e composições como inibidores de proteìna cinase
JP2008502595A (ja) 2004-03-31 2008-01-31 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
JP2009528295A (ja) * 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
WO2008051547A1 (en) * 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
UA100846C2 (ru) * 2006-12-08 2013-02-11 Айерем Елелсі Соединения и композиция как ингибиторы протеинкиназы
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
SG175707A1 (en) * 2009-06-10 2011-12-29 Chugai Pharmaceutical Co Ltd Tetracyclic compound
CA2865420C (en) * 2012-03-06 2020-06-02 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EP3237408B1 (en) * 2014-12-23 2018-10-31 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Also Published As

Publication number Publication date
CN106166155B (zh) 2019-01-18
JP6016953B2 (ja) 2016-10-26
JP2015509540A (ja) 2015-03-30
US20150011561A1 (en) 2015-01-08
EP2822939B1 (en) 2016-02-17
KR20140138247A (ko) 2014-12-03
US20190328735A1 (en) 2019-10-31
JP2017039741A (ja) 2017-02-23
CL2014002353A1 (es) 2015-01-09
US9339502B2 (en) 2016-05-17
HK1226300A1 (zh) 2017-09-29
SI2822939T1 (sl) 2016-04-29
NZ630251A (en) 2016-02-26
ES2681487T3 (es) 2018-09-13
UA115052C2 (uk) 2017-09-11
IL252364B (en) 2018-03-29
IL234239A (en) 2017-06-29
EP2822939A1 (en) 2015-01-14
EA025859B1 (ru) 2017-02-28
US10111872B2 (en) 2018-10-30
MX2014010613A (es) 2014-09-18
CY1117565T1 (el) 2017-04-26
US9623026B2 (en) 2017-04-18
EP3056494B1 (en) 2018-05-02
RS54689B1 (en) 2016-08-31
EA201691574A1 (ru) 2017-03-31
MX347772B (es) 2017-05-12
WO2013134353A1 (en) 2013-09-12
EP3056494A1 (en) 2016-08-17
CA2865420C (en) 2020-06-02
HRP20160387T1 (hr) 2016-05-20
ZA201406147B (en) 2015-12-23
HUE027976T2 (en) 2016-11-28
CN104159894B (zh) 2016-09-07
AU2013229995B2 (en) 2017-04-13
ES2570976T3 (es) 2016-05-23
US20160243119A1 (en) 2016-08-25
PH12014501979B1 (en) 2014-11-24
US9132128B2 (en) 2015-09-15
EA033124B1 (ru) 2019-08-30
DK2822939T3 (en) 2016-03-14
WO2013134353A8 (en) 2014-06-19
AU2013229995A1 (en) 2014-09-25
PH12014501979A1 (en) 2014-11-24
SG10201507865QA (en) 2015-10-29
SMT201600134B (it) 2016-07-01
CN104159894A (zh) 2014-11-19
CN106166155A (zh) 2016-11-30
MY177290A (en) 2020-09-10
US20170173017A1 (en) 2017-06-22
US20150374693A1 (en) 2015-12-31
HK1205119A1 (zh) 2015-12-11
CA2865420A1 (en) 2013-09-12
SG11201405371PA (en) 2014-09-26
KR102068374B1 (ko) 2020-01-20
ME02460B (me) 2017-02-20
IL252364A0 (en) 2017-07-31
US10632119B2 (en) 2020-04-28
PL2822939T3 (pl) 2016-08-31

Similar Documents

Publication Publication Date Title
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
EA201590661A1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201500362A1 (ru) Ингибиторы rho-киназы
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
IN2014CN04558A (ru)
EA201690844A1 (ru) Ингибиторы gsk-3
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
MX366839B (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4.
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
EA201790209A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde
EA201491641A1 (ru) Конденсированное бициклическое 2,4-диаминопиримидиновое производное в качестве двойного alk и fak ингибитора
EA201690818A1 (ru) Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов
EA201692140A1 (ru) Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM